Open an account

Serina Therapeutics

SER · NYSE American

$1.66+$0.01 (+0.61%)TodayMarket closed ·
Prev close $1.65

About SER

Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. The company is headquartered in Huntsville, Alabama and currently employs 16 full-time employees. The company went IPO on 2018-11-29. The firm's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.

Employees
16
Headquarters
Huntsville, Alabama
Listed
Nov 29, 2018
Sector
Health Care
Industry
Biotechnology
Website
serinatherapeutics.com

SER key statistics

Market cap
42.16M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
32.71K
Volume
42.13K
Open price
$1.64
High today
$1.74
Low today
$1.63
52 Week high
$5.29
52 Week low
$1.22

Serina Therapeutics (SER) at a glance

As of Oct 20, 2026, Serina Therapeutics (SER) shares are priced at $1.66, giving the company a market cap of 42.16M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.63 and $1.74. The current price is 1.8% above the day's low and 4.3% below its high.

Volume so far is 42.13K shares, above the average of 32.71K shares a day.

Over the past year Serina Therapeutics has ranged from $1.22 to $5.29, and now sits 11% of the way up that range.

Serina Therapeutics met or beat analyst EPS estimates in 3 of the last 7 quarters. In Q2 FY26 it reported -$0.55 per share against an estimate of -$0.4697.

The average analyst price target is $9.69, 483.7% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $9.69
Low
$8.08
Now
$1.66
High
$11.55

SER earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 7 quarters, by 19.9% on average.

  1. Q3 FY23: reported -$0.14 per share against an estimate of $0.00
  2. Q1 FY25: reported -$0.49 per share against an estimate of -$0.6262
  3. Q2 FY25: reported -$0.66 per share against an estimate of -$0.4293
  4. Q3 FY25: reported -$0.51 per share against an estimate of -$0.5353
  5. Q4 FY25: reported -$0.31 per share against an estimate of -$0.4646
  6. Q1 FY26: reported -$0.58 per share against an estimate of -$0.4444
  7. Q2 FY26: reported -$0.55 per share against an estimate of -$0.4697

SER news

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Rishabh Mishra

    Stock Market Today: Futures Drop Ahead Of 'Triple Witching' Session As Iran Threatens 'Zero Restraint'— FedEx, Super Micro In Focus (UPDATED)

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Gold Tumbles Over 6%; Accenture Earnings Top Views

  • Avi Kapoor

    Dow Falls Over 300 Points; US Initial Jobless Claims Fall

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

Similar companies

Companies in the same industry as Serina Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.